#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11634	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2116	539.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1677	1677	T	590	T,C	566,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11634	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2116	539.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	651	C	636	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	11634	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2116	539.2	0	HET	.	.	.	C1320T,A	.	1320	1320	C	1547	1547	C	667	C,T,A	332,319,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21136	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3732	561.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1761	1761	A	710	A,G	700,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21136	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3732	561.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2395	2395	C	668	C	653	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21136	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3732	561.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2469	2469	A	660	A	651	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	21136	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3732	561.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3021	3021	C	589	C,T	580,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1568	folP	855	855	100.0	folP.l15.c4.ctg.1	1598	97.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1100	1102	AGC	147;147;148	A;G;C	143;145;144	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	4506	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3560	125.5	1	SNP	p	S91F	1	.	.	271	273	TTC	713	715	TTC	142;142;141	T;T;C	136;138;135	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	4506	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3560	125.5	1	SNP	p	D95G	1	.	.	283	285	GGC	725	727	GGC	129;131;131	G;G;C	125;128;126	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	283	4506	gyrA	2751	2751	99.96	gyrA.l6.c30.ctg.1	3560	125.5	1	SNP	p	G95N	0	.	.	283	285	GGC	725	727	GGC	129;131;131	G;G;C	125;128;126	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1392	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1430	96.3	1	SNP	p	G45D	0	.	.	133	135	GGC	514	516	GGC	158;154;151	G;G;C,G	154;148;145,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	736	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1043	69.6	0	.	n	.	0	A197.	DEL	197	197	A	570	570	A	146	A	146	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	0	.	p	.	0	G120R	NONSYN	358	360	GGG	714	716	AGG	151;151;153	A,G;G;G	145,1;150;152	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1506	1508	GTC	160;160;161	G;T;C,A	154;154;156,1	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	1	SNP	p	D86N	0	.	.	256	258	GAC	612	614	GAC	145;143;144	G;A;C	141;133;139	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	1	SNP	p	R87I	0	.	.	259	261	CGT	615	617	CGT	142;142;142	C;G,A;T,G,C	139;139,1;131,1,1	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	1	SNP	p	R87W	0	.	.	259	261	CGT	615	617	CGT	142;142;142	C;G,A;T,G,C	139;139,1;131,1,1	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	1	SNP	p	S87R	1	.	.	259	261	CGT	615	617	CGT	142;142;142	C;G,A;T,G,C	139;139,1;131,1,1	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	3868	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3194	120.0	1	SNP	p	S88P	0	.	.	262	264	TCC	618	620	TCC	140;141;141	T;C;C	135;136;138	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3302	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2666	122.5	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1358	1360	TGC	127;124;121	T;G;C	123;121;119	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3302	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2666	122.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1568	1570	GGC	151;149;147	G;G;C,T	148;145;142,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1296	1298	GCA	134;133;133	G;C;A	132;129;131	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1299	1301	ATC	132;132;132	A;T;C	129;130;130	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1311	1313	GTG	127;124;122	G;T;G	124;122;121	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1311	1313	GTG	127;124;122	G;T;G	124;122;121	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1815	1817	ACC	137;136;135	A;C;C	129;132;130	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1869	1871	GCG	125;125;128	G;C,G;G	120;108,5;122	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1869	1871	GCG	125;125;128	G;C,G;G	120;108,5;122	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1992	1994	GGC	99;97;99	G;G;C	97;94;95	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2001	2003	GGC	97;93;94	G,A;G;C	94,1;91;91	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	2944	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2500	116.6	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2019	2021	TCG	88;89;88	T,G;C,G;G,C	60,8;79,1;77,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4624	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3195	143.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1701	1703	CCG	149;150;148	C;C;G	139;145;137	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1994	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1801	109.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	563	563	C	153	C	146	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	467	469	GAA	180;177;178	G;A;A	179;177;177	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	755	757	GAT	168;168;168	G;A;T	167;163;165	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	878	880	TCA	164;162;160	T;C;A	156;157;158	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1007	1009	GTC	160;155;155	G;T;C	155;149;154	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1337	1339	GCA	167;164;166	G;C;A	164;162;162	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	1	SNP	p	G120K	1	.	.	358	360	AAG	713	715	AAG	157;161;164	A;A;G	153;156;158	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	1	SNP	p	D121N	0	.	.	361	363	GAC	716	718	GAC	165;163;164	G;A;C	160;155;159	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2186	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1644	131.6	1	SNP	p	A121D	1	.	.	361	363	GAC	716	718	GAC	165;163;164	G;A;C	160;155;159	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7452	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4871	151.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2062	2064	AAT	155;150;149	A;A;T	153;148;148	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	876	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1256	69.5	1	SNP	p	V57M	1	.	.	169	171	ATG	588	590	ATG	164;164;165	A;T;G	164;161;161	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
